Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5

Benzinga Newsdesk www.benzinga.com Negative 59.7%

Neg 59.7% Neu 0% Pos 0%

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.